Last reviewed · How we verify
Recombinant fimbrial adhesin dscCfaE — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
Recombinant fimbrial adhesin dscCfaE (Recombinant fimbrial adhesin dscCfaE) — U.S. Army Medical Research and Development Command.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Recombinant fimbrial adhesin dscCfaE TARGET | Recombinant fimbrial adhesin dscCfaE | U.S. Army Medical Research and Development Command | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Recombinant fimbrial adhesin dscCfaE CI watch — RSS
- Recombinant fimbrial adhesin dscCfaE CI watch — Atom
- Recombinant fimbrial adhesin dscCfaE CI watch — JSON
- Recombinant fimbrial adhesin dscCfaE alone — RSS
Cite this brief
Drug Landscape (2026). Recombinant fimbrial adhesin dscCfaE — Competitive Intelligence Brief. https://druglandscape.com/ci/recombinant-fimbrial-adhesin-dsccfae. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab